<i>In vivo</i> Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic CarcinomasChristel Larbouret, D. Azria|Clinical Cancer Research|2007Cited by 84
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenograftsChristel Larbouret, D. Azria|Annals of Oncology|2009Cited by 49
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsGaëlle Thomas, Christel Larbouret|Oncotarget|2014Cited by 44